Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD41/CD61 (PAC-1 epitope) PE

Anti-Hu CD41/CD61 (PAC-1 epitope) PE

Regulatory status

RUO

Antigen

CD41/CD61 (PAC-1 epitope)

Clone

PAC-1

Format

Reactivity

Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

1P-145-T100

In stock

242.00 USD

Variant

100 tests

1P-145-T100

In stock

242.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgM kappa

Specificity

The mouse monoclonal antibody PAC-1 recognizes an extracellular activation-induced conformational epitope PAC-1 on CD41/CD61 complex (gpIIb/IIIa), also known as integrin alpha IIb beta 3, a receptor which mediates platelet aggregation.

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

Human platelets

Preparation

Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

platelet GPIIb, Integrin alpha-Iib, GPalpha IIb, GPIIb, GT, GP3A, platelet GPIIIa

Antigen description

CD41 (platelet glycoprotein IIb, integrin alpha IIb) is composed of two subunits (120 kDa transmembrane alpha chain and 23 kDa extracellular beta chain) and interacts with CD61 (platelet glycoprotein IIIa, integrin beta 3) in the presence of calcium to form a functional adhesive protein receptor. CD41/CD61 complex is one of the earliest markers of the megakaryocytic lineage. Upon blood vessel damage, this receptor binds to a variety of proteins including von Willebrand factor, fibrinogen, fibronectin and vitronectin, and it is involved in platelet aggregation.

Flow cytometry surface staining pattern of PHA stimulated human peripheral whole blood stained using anti-human CD41/CD61 (PAC-1) PE antibody (10 μl reagent / 100 μl of peripheral whole blood).

Separation of CD41/CD61 positive thrombocytes (red-filled) from CD41/CD61 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of PHA stimulated human peripheral whole blood using anti-human CD41/CD61 (PAC-1) PE antibody (10 μl reagent / 100 μl of peripheral whole blood).

Product specific references:

Shattil SJ, Hoxie JA, Cunningham M, Brass LF: Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem. 1985 Sep 15;260(20):11107-14.
PubMed

Shattil SJ, Cunningham M, Hoxie JA: Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 1987 Jul;70(1):307-15.
PubMed

Trikha M, Timar J, Lundy SK, Szekeres K, Cai Y, Porter AT, Honn KV: The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells. Cancer Res. 1997 Jun 15;57(12):2522-8.
PubMed

Bourne JH, Colicchia M, Di Y, Martin E, Slater A, Roumenina LT, Dimitrov JD, Watson SP, Rayes J: Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica. 2021 Feb 1;106(2):626-629.
PubMed